2017 did not bring a lot of new life science companies to Switzerland. However, the total value of the venture financing of existing companies was twice as high as it was in 2016 with over 600 million USD invested. The largest amount went to ADC Therapeutics Inc and will be used to progress their products indicated for hematological tumors.
Swiss Life Science Trend Analysis 2018
Looking for your next Biotech or Medtech partner?
Use Biotechgate to identify new leads, licensing opportunities and management details.